A Safety and Pharmacokinetic Study of IGM-2323 in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma
Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1 study of IGM-2323 in adult subjects with relapsed or refractory B-cell
Non-Hodgkin Lymphoma. This study will consist of a dose-escalation stage and a dose-expansion
stage where subjects will be enrolled into indication-specific expansion cohorts. IGM-2323
will be administered intravenously (IV).
Additional CD20-positive NHL histologies (e.g. MZL and MCL), may be allowed with Medical
Monitor approval during the Dose-Escalation Phase of the study.